As a health journalist, I’m doing my best to keep up with all things weight loss drugs, but with headlines rolling in every ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that delivered weight loss success by taking a daily pill.

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data ...

Ozempic, Wegovy, Mounjaro, Zepbound ... especially with the prospect of a daily pill form on the horizon. Millions of Americans have taken the drugs, known collectively as GLP-1 agonist medications.

Amycretin, an oral weight loss pill developed by the makers of Wegovy, led to a 13.1% weight loss over three months in early ...